American Association for Cancer Research
crc-22-0368-s06.pdf (414.76 kB)

Figure S5 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes

Download (414.76 kB)
journal contribution
posted on 2023-04-04, 02:21 authored by Cindy Lin, Laura Garcia-Gerique, Erin E. Bonner, Jerome Mastio, Matthew Rosenwasser, Zachary Cruz, Michael Lawler, Luca Bernabei, Kar Muthumani, Qin Liu, Mortimer Poncz, Thomas Vogl, Marie Törngren, Helena Eriksson, Dan T. Vogl, Dmitry I. Gabrilovich, Yulia Nefedova

BM angiogenesis in tumor-free and MM-bearing mice treated with TQ.


HHS | NIH | National Cancer Institute (NCI)

Pennsylvania Department of Health (PA DOH)

American Association for Cancer Research (AACR)

Interdisciplinary Center of Clinical Research at the University of Münster

German Research Foundation

Active Biotech (Active Biotech AB)



We identified a novel mechanism by which myeloid cells promote myeloma progression independently of the adaptive immune system. Specifically, we discovered a novel role of S100A8/S100A9, the most abundant proteins produced by neutrophils and monocytes, in regulation of myeloma progression via promotion of the megakaryocyte expansion and angiogenesis. Tasquinimod, an inhibitor of S100A9, has potent antimyeloma effects as a single agent and in combination with lenalidomide and with proteasome inhibitors.